~~<i id='DE0DEE9B66'><strike id='DE0DEE9B66'><tt id='DE0DEE9B66'><pre id='DE0DEE9B66'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：leisure time 2025-09-29 19:05:19 - browse：4788

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Pharmacists can make shortage drugs, but at what cost?

focus

explore

leisure time

explore

focus

RonaldWittek,PoolPhotoviaAPToday,thecriteriausedtoassesstheclinicalvalueofnewpharmaceuticalsandmedic

WSS

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Future doctors should be trained to promote social change

Gene editing the human germline: What are the risks?

Senate committee scrutinizes Medicare Advantage brokers

Lawmakers consider Medicare pay reforms for doctors

Nurses recount patients attacks

knowledge

fashion

focus

Dobbs anniversary: the lost opportunity of abortion as health care

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Health AI adoption puts security, privacy startups on investors' radar

Alkermes shareholders re

How climate

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Baby aspirin cuts fat buildup in liver disease patients, in small study

23andMe had bad news about my health. I wish a person had delivered it

Methadone treatment changes are coming. Do they go far enough?

explore

Will Ozempic

Senate committee scrutinizes Medicare Advantage brokers

Intermittent fasting comes with a heart risk? Not so fast

SCOTUS questions limit to govt efforts to fight misinformation

Readout Newsletter: Bluebird, CVS, Contineum

Orchard's therapy for neuron disease in children wins FDA approval

leisure time

leisure time

explore

focus